Cancer specific deaths number | Controls number | OR (95% CI) | P | OR (95% CI) | P | |
---|---|---|---|---|---|---|
ACEI user versus non user | ARB user versus non user | |||||
Prostate cancer | ||||||
Main analysis: diagnosis to six months prior to deatha | 766 | 3,777 | 0.82 (0.67, 1.02) | 0.07 | 0.82 (0.61, 1.11) | 0.21 |
Diagnosis to one year prior to deathb | 682 | 3,360 | 0.88 (0.70, 1.09) | 0.24 | 0.89 (0.64, 1.23) | 0.48 |
Adjusting for Gleason score along with all variables ina apart from grade | 516 | 2,518 | 0.80 (0.62, 1.03) | 0.09 | 0.89 (0.61, 1.31) | 0.55 |
Restricted to users of any antihypertensive medicationc prior to cancer diagnosisd | 399 | 1,925 | 0.80 (0.62, 1.04) | 0.09 | 0.89 (0.62, 1.26) | 0.51 |
Comparison group restricted to users of any antihypertensive in exposure periodc | 584 | 2,753 | 0.78 (0.63, 0.96) | 0.02 | 0.80 (0.59, 1.08) | 0.15 |
Additionally adjusting for other antihypertensivese | 766 | 3,777 | 0.74 (0.60, 0.92) | 0.01 | 0.75 (0.55, 1.02) | 0.07 |
Additionally adjusting for hormone therapy any time after diagnosisf | 766 | 3,777 | 0.82 (0.66, 1.01) | 0.06 | 0.84 (0.62, 1.14) | 0.27 |
≥730 DDDs versus 0 DDDs (non-user) | 766 | 3,777 | 0.91 (0.70, 1.18) | 0.49 | 0.84 (0.59, 1.21) | 0.36 |
Pre-diagnostic useg | 821 | 4,041 | 0.98 (0.78, 1.23) | 0.87 | 1.14 (0.75, 1.75) | 0.53 |
Time varying covariate analysish | 772 | 3,838 | ||||
≥1 DDDs versus 0 DDDs (non-user) | 0.90 (0.76, 1.07) | 0.24 | 0.95 (0.73, 1.23) | 0.70 | ||
1 to 365 DDDs versus 0 DDDs (non-user) | 0.87 (0.70, 1.08) | 0.21 | 0.88 (0.62, 1.26) | 0.49 | ||
≥365 DDDs versus 0 DDDs (non-user) | 0.94 (0.76, 1.18) | 0.60 | 1.03 (0.72, 1.48) | 0.86 |